Kateryna🇺🇦

Ukrainian 🇺🇦❤️ Postdoctoral Fellow @HaydnKissick lab Emory University; PhD Niedermann lab @UniFreiburg @RadOnc_UKF @DKTK_

[Kateryna🇺🇦 @KatOnyshchenko]

Excited to share the major part of my PhD work finally published in @NatureComms ! Here we investigated the impact of adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies, and how this affects the systemic anti-tumor T cell response.
https://t.co/Se46y3F92I

[Open Box Science @OpenBoxSci]

@Maria_Carden1 talk is now on YouTube!
📣 Differentiation fate of a stem-like CD4 T cells control immunity to Cancer
@HaydnKissick lab @EmoryMedicine
https://t.co/IpdV6qyII8

[Zhuldyz Zhanzak @Zhuldyz_Zhanzak]

Excited to share my PhD work in @ImmunityCP . We show CD4 T cell epitopes related to rejection. Through computational prediction and functional studies in humans and mice, we bridge fundamental research and clinical application. Special thanks to @clarsenEmory and @HaydnKissick!

[ACIR @ACIR_org]

McManus and Valanparambil et al. showed that nearly identical stem-like (PD-1+TCF-1+TOX+) CD8+ T cells emerged as early as day 5 during chronic and acute LCMV infections. https://t.co/gFcXMZSfUg  @rafiahmed_lab  @dmcmanus123

[Daniel McManus, PhD @dmcmanus123]

Excited to share my PhD work from @rafiahmed_lab. We show how CD8 T cells overcome the inability to predict how long a viral infection will last by making adaptable precursor cells a priori—an elegant strategy for an inherently non-prescient immune system. https://t.co/etxUUtbQg2

[Haydn Kissick @HaydnKissick]

Check out our latest paper “Differentiation fate of a stem-like CD4 T cell control immunity to cancer”, led by @Maria_Carden1 now live @Nature https://t.co/CrbGlEdQja . This work examines how CD4 T cell differentiation dictates the outcome of the cancer response. Thread below

[Maria Andrea Cardenas @Maria_Carden1]

I am so excited to share my first author publication, “Differentiation fate of a stem-like CD4 T cell control immunity to cancer” published today in
@nature, detailing the project I’ve been working on in
@HaydnKissick’s lab. https://t.co/byzaSwNkwV

[Kateryna🇺🇦 @KatOnyshchenko]

@RenLuo_RAD Congrats 👏

[Kateryna🇺🇦 @KatOnyshchenko]

Congratulations! Excited to see the amazing science that lies ahead.

[Aitziber Buqué @txi_ber]

I'm deeply honored to join this historic institution and contribute to its legacy. I'm excited to tackle the innovative projects ahead and be a part of shaping its future. @FoxChaseCancer #BreastCancer #NewPI #WomenInSTEM @ASEICAnews #CONÓCELAS @comunidadECUSA @sitcancerECS

[Andy Minn @andyjminn]

Summary of our paper https://t.co/1CE0c2kHUO on combining JAK inhibitors with anti-PD1 for lung cancer (NSCLC). Part of a bench-to-bedside journey to understand opposing roles of IFN in IO. Wonderful team w @EJohnWherry @divijmathew Caitlin Foley @MMarmarelis @Jbauml et al! 1/13

[Kateryna🇺🇦 @KatOnyshchenko]

@GaiplS @GabiNiedermann @RadOnc_UKF Thank you🙏

[Kateryna🇺🇦 @KatOnyshchenko]

Thrilled to receive the #DEGRO2024 Dissertation Prize! Many thanks to @GabiNiedermann and colleagues at @RadOnc_UKF for the support!

[Kateryna🇺🇦 @KatOnyshchenko]

@txi_ber @FoxChaseCancer That’s amazing, congratulations 👏👏👏

[Kateryna🇺🇦 @KatOnyshchenko]

Check out our new paper shedding light on the mechanism of lenalidomide-mediated improvement of the RT-induced abscopal effect in solid tumor models, published this week in Theranostics 👏👏👏@RenLuo_RAD @ElkeFirat @GabiNiedermann @RadOnc_UKF @DKTK_
https://t.co/4B8vdNwf05

[Kateryna🇺🇦 @KatOnyshchenko]

@careyjans @YaleMedPSTP @TradIMYale @YaleIM_Chiefs @A_P_S_A @WinshipAtEmory @EmoryMSTP @EmoryMedicine Congratulations! 🎉

[Kateryna🇺🇦 @KatOnyshchenko]

Thesis defended, PhD journey complete! ✅🎓 Ready to dive into new, exciting adventures and opportunities 🎉

[Kateryna🇺🇦 @KatOnyshchenko]

Excited to be back in Paris for #Immunorad2023 – the best radioimmunology conference. This event holds a special place in my heart as it was the first conference I attended during my PhD and now, at the culmination of this incredible journey, I'm honored to be here again.

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING https://t.co/xw8X6djxLp @liqunwang3 @RenLuobu @KatOnyshchenko @GabiNiedermann

[Kateryna🇺🇦 @KatOnyshchenko]

Ready for the Immun-Radioonkologie morning section at #DEGRO2023

[Radiation Oncology University Freiburg @RadOnc_UKF]

Congratulations to @Simon_Spohn for receiving the ARO trial award by @DKG_Berlin at #DEGRO2023 for the #HypoFocal-SBRT Phase 3 trial protocol.
Join the trial !
@Uniklinik_Fr @degro_ev @AncaGrosu1 @CZamboglou

[Kateryna🇺🇦 @KatOnyshchenko]

Had an incredible time at #ESTRO2023 @ESTRO_RT, learning from some of the top minds in the field and sharing our latest preclinical data on RT/anti-PD1/IL-2c combo treatment!